GlobeNewswire

EnvoyAI, Ambra Health, and TeraRecon Deliver First End-to-End AI Strategy

Dela

Leading AI, image sharing, and advanced viewing platforms simplify AI access and workflow

 

Las Vegas, NV (HIMSS18), March 06, 2018 (GLOBE NEWSWIRE) -- Las Vegas, NV - March 6th, 2018 -  TeraReconEnvoyAI, and Ambra Health, today announced a new collaboration to provide an AI-enhanced image exchange workflow. The partnership will enable healthcare providers to immediately implement an AI strategy through an Ambra image exchange workflow with access to the entire portfolio of AI algorithm solutions available on the EnvoyAI Exchange, leveraging their current PACS system or the full range of TeraRecon viewers. These AI workflows will be on display at the Healthcare Information & Management Systems Society (HIMSS18) annual meeting in Las Vegas, Nevada March 6th- 8th, 2018.

Andrew Duckworth, VP of Business Development of Ambra Health shared, "This interoperability partnership gives healthcare providers in the Ambra network access to bleeding edge AI technology for advanced image visualization, providing the very latest technological innovations to continually improve patient outcomes and care."

The EnvoyAI platform has continued to grow since the recent launch at RSNA17, with the partner count now standing at 20 contracted companies, contributing a total of 48 products, of which 10 have already achieved FDA-clearance.

TeraRecon's flagship product, iNtuition, provides advanced visualization capabilities, which now include embedded EnvoyAI image analysis engines within the typical advanced visualization workflow. iNtuition is already integrated with many leading PACS providers, so thousands of TeraRecon customers immediately have a way to implement a tightly integrated AI workflow that fits within their current PACS systems.

At HIMSS18, TeraRecon is also debuting the world's first AI results viewer, Northstar(TM). Newly-added features allow the latest version of the prototype viewer to interact with EnvoyAI results, providing the ability to accept, reject, and even adjust the EnvoyAI-derived findings.

Jeff Sorenson, CEO of TeraRecon stated: "Northstar is designed to be effortlessly embedded into all major PACS viewing platforms for an instant end-to-end AI strategy that spans from the selection of algorithms to the final end-user experience. Now, via the Ambra Health platform, our reach extends even further, to referring physicians needing access to AI and who require our industry-leading iNtuition advanced interpretation tools."

Jake Taylor, CTO of EnvoyAI, stated, "Through our partnerships with Ambra Health and TeraRecon, our technology can reach remote, single physician practices while also meeting the most demanding clinical needs of the largest integrated health systems."

To receive a demonstration of the integrated solution at HIMSS18, visit Ambra Health at booth #8324. EnvoyAI will be located at distribution partner, TeraRecon's, booth #3900. Online demonstrations are also available by contacting Ambra Health at info@ambrahealth.com or EnvoyAI at info@envoyai.com.

About TeraRecon (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry's leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency.

About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Ambra Health ( www.ambrahealth.com Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers some of the largest health systems such as Memorial Hermann, Stanford Children's Health and New England Baptist Hospital as well as radiology practices, subspecialty practices and clinical research organizations to dramatically improve imaging and collaborative care workflows. As expert partners, we listen to our customers, understand their needs, and apply our extensive knowledge to deliver innovative medical image management solutions for the future of healthcare, now. Discover what the Ambra medical imaging cloud can do for you.

Press Inquiries US: 1-650-372-1100 | info@terarecon.com

Attachment:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2597c384-2480-4c75-8eee-959b45f42aae

Lindsay Fleming
TeraRecon
6506534319
lindsay@terarecon.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum